anx_I__cpt_22__cpt_1__cpt_2__text_3

Similarly, the complexity of the challenge and the interdependency of its components demand a European level response. Many approaches, tools and technologies have applicability across many of the research and innovation areas of this challenge and are best supported at Union level. These include understanding the molecular basis of disease, the identification of innovative therapeutic strategies and novel model systems, the multidisciplinary application of knowledge in physics, chemistry and systems biology, the development of long-term cohorts and the conduct of clinical trials (including focus on the development and effects of medicines in all age groups), the clinical use of "-omics", systems biomedicine and the development of ICT and their applications in healthcare practice, notably e-health. The requirements of specific populations are also best addressed in an integrated manner, for example in the development of stratified and/or personalised medicine, in the treatment of rare diseases, and in providing assisted and independent living solutions.

← anx_I__cpt_22__cpt_1__cpt_2__text_2 · All articles · anx_I__cpt_22__cpt_1__cpt_2__text_4 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-03 · Text as adopted (Official Journal); later amendments are not incorporated in this text.